Dashboard
Manage Tickers

ESPREsperion Therapeutics, Inc.

Nasdaq esperion.com


$ 2.36 $ 0.10 (4.2 %)    

Monday, 01-Jul-2024 14:28:23 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.94 $ 0.65 (0.14 %)
DIA $ 391.72 $ 0.59 (0.15 %)
SPY $ 544.87 $ -0.54 (-0.1 %)
TLT $ 89.86 $ -0.55 (-0.61 %)
GLD $ 215.29 $ 0.28 (0.13 %)
$ 2.22
$ 2.26
$ 2.35 x 200
$ 2.36 x 1,000
$ 2.22 - $ 2.50
$ 0.70 - $ 3.40
61,408,848
na
421M
$ 0.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-01-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-21-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-02-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 02-22-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-23-2021 12-31-2020 10-K
15 11-02-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-02-2018 03-31-2018 10-Q
26 02-20-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-22-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-04-2016 03-31-2016 10-Q
34 02-25-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 03-10-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-12-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-esperion-therapeutics-maintains-8-price-target
Needham Reiterates Buy on Esperion Therape...
06/28/2024 17:32:37

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $8 price target.

hc-wainwright--co-reiterates-buy-on-esperion-therapeutics-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Espe...
06/28/2024 15:08:29

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

esperion-therapeutics-shares-are-trading-higher-after-the-company-announced-that-it-entered-into-a-royalty-purchase-agreement-with-omers-life-sciences
Esperion Therapeutics shares are trading h...
06/28/2024 11:39:06

esperion-says-it-enters-into-a-royalty-purchase-deal-with-omers-life-sciences-under-which-it-got-3047m-in-exchange-for-100-interest-in-esperions-royalty-entitlement-on-daiichi-sankyo-europes-net-sales-of-bempedoic-acid-products-in-europe
Esperion Says It Enters Into A Royalty Pur...
06/28/2024 11:06:13

why-jabil-shares-are-trading-lower-by-8-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Jabil Shares Are Trading Lower By 8%? ...
06/20/2024 17:26:29

workday-to-rally-over-52-here-are-10-top-analyst-forecasts-for-thursday
Workday To Rally Over 52%? Here Are 10 Top...
06/20/2024 12:11:28

b-of-a-securities-downgrades-esperion-therapeutics-to-underperform-lowers-price-target-to-25
B of A Securities Downgrades Esperion Ther...
06/20/2024 10:36:03

B of A Securities analyst Jason Zemansky downgrades Esperion Therapeutics (NASDAQ:ESPR) from Neutral to Underperform and low...

why-skye-bioscience-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Skye Bioscience Shares Are Trading Low...
06/10/2024 18:10:40

argan-reports-strong-earnings-joins-geron-planet-labs-pbc-and-other-big-stocks-moving-higher-on-friday
Argan Reports Strong Earnings, Joins Geron...
06/07/2024 14:19:37

hc-wainwright--co-reiterates-buy-on-esperion-therapeutics-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Espe...
05/22/2024 15:59:51

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

european-commission-approve-nilemdo-and-its-combination-with-ezetimibe-nustend-for-hypercholesterolemia-and-reduce-cardiovascular-risk
European Commission Approve NILEMDO And It...
05/22/2024 12:08:01

– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) R...

hc-wainwright--co-reiterates-buy-on-esperion-therapeutics-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Espe...
05/21/2024 09:42:24

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

esperion-therapeuticsotsuka-partnered-cholesterol-drug-shows-effective-in-japan-study
Esperion Therapeutics/Otsuka Partnered Cho...
05/20/2024 18:22:42

Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant...

esperion-otsuka-report-primary-endpoint-was-achieved-in-phase-3-trial-in-japan-for-bempedoic-acid-as-potential-treatment-for-patients-with-hypercholesterolemia
Esperion, Otsuka Report Primary Endpoint W...
05/20/2024 10:02:32

The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potent...

esperion-receives-five-year-patent-extension-for-bempedoic-acid
Esperion Receives Five Year Patent Extensi...
05/14/2024 12:16:02

hc-wainwright--co-reiterates-buy-on-esperion-therapeutics-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Espe...
05/08/2024 13:33:12

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

needham-reiterates-buy-on-esperion-therapeutics-maintains-8-price-target
Needham Reiterates Buy on Esperion Therape...
05/07/2024 17:57:08

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $8 price target.

heart-disease-drugmaker-esperion-therapeutics-reports-highest-revenue-yet-stock-soars
Heart Disease Drugmaker Esperion Therapeut...
05/07/2024 14:20:54

Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA...

correction-esperion-therapeutics-sees-fy24-operating-expenses-225m-245m-including-20m-in-non-cash-expenses-related-to-stock-compensation
CORRECTION: Esperion Therapeutics Sees FY2...
05/07/2024 14:19:57

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/07/2024 12:06:20

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)